Kaken Pharmaceutical Co., Ltd.
KKPCFOTCHealthcare● Active
$26.78
+$0.78(+3.00%)
Market Cap$1.0B
P/E Ratio—
52W High$28.121
52W Low$22.3
Kaken Pharmaceutical Co., Ltd. (KKPCF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
KKPCF · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
$0.12
Est. $0.13 · -1.4%
Revenue
$0.12B
Est. $0.14B · -15.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
KKPCF reports quarterly as a OTC-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 30, 2026 | — | — | — | — | — | — |
| ▼ Q2 FY2026 | May 13, 2026 | $0.13 | $0.12 | -1.4% | $0.12B | $0.14B | -15.1% |
| ▼ Q1 FY2026 | Feb 6, 2026 | $0.16 | $0.07 | -56.8% | $0.12B | $0.12B | -5.8% |
| — Q4 FY2025 | Nov 10, 2025 | — | $0.13 | — | $0.14B | — | — |
| — Q3 FY2025 | Aug 5, 2025 | — | $0.05 | — | $0.13B | — | — |
| — Q2 FY2025 | May 12, 2025 | — | -$0.94 | — | $0.12B | — | — |
| — Q1 FY2025 | Feb 6, 2025 | — | $0.82 | — | $0.16B | — | — |
| — Q4 FY2024 | Nov 8, 2024 | — | $2.23 | — | $0.22B | — | — |
Q3 FY2026
Jul 30, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Miss
EPS Actual
$0.12
EPS Est.
$0.13
EPS Surpr.
-1.4%
Revenue
$0.12B
Q1 FY2026
Feb 6, 2026Miss
EPS Actual
$0.07
EPS Est.
$0.16
EPS Surpr.
-56.8%
Revenue
$0.12B
Q4 FY2025
Nov 10, 2025
EPS Actual
$0.13
EPS Est.
—
EPS Surpr.
—
Revenue
$0.14B
Q3 FY2025
Aug 5, 2025
EPS Actual
$0.05
EPS Est.
—
EPS Surpr.
—
Revenue
$0.13B
Q2 FY2025
May 12, 2025
EPS Actual
-$0.94
EPS Est.
—
EPS Surpr.
—
Revenue
$0.12B
Q1 FY2025
Feb 6, 2025
EPS Actual
$0.82
EPS Est.
—
EPS Surpr.
—
Revenue
$0.16B
Q4 FY2024
Nov 8, 2024
EPS Actual
$2.23
EPS Est.
—
EPS Surpr.
—
Revenue
$0.22B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2026 | $20.11 | $20.11 | $20.11 | 1 |
| Q4 FY2025 | $24.81 | $24.81 | $24.81 | 1 |
| Q3 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2026 | $22.8B | $22.8B | $22.8B | 1 |
| Q4 FY2025 | $19.4B | $19.4B | $19.4B | 1 |
| Q3 FY2025 | $20.8B | $20.8B | $20.8B | 1 |
| Q2 FY2025 | $18.9B | $18.9B | $18.9B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 13, 2026 | -1.4% | $26.00 | $26.00 | +0.00% |
| ▼ Q1 FY2026 | Feb 6, 2026 | -56.8% | $26.00 | $26.00 | +0.00% |
| — Q4 FY2025 | Nov 10, 2025 | — | $24.00 | $24.00 | +0.00% |
| — Q3 FY2025 | Aug 5, 2025 | — | $28.09 | $28.09 | +0.00% |
| — Q2 FY2025 | May 12, 2025 | — | $26.31 | $28.09 | +6.77% |
| — Q1 FY2025 | Feb 6, 2025 | — | $26.31 | $26.31 | +0.00% |
| — Q4 FY2024 | Nov 8, 2024 | — | $24.01 | $24.01 | +0.00% |
| — Q3 FY2024 | Aug 7, 2024 | — | $27.92 | $27.92 | +0.00% |
Q2 FY2026+0.00%
Report Date
May 13, 2026
EPS Beat/Miss
-1.4%
Price Before
$26.00
Price After
$26.00
Q1 FY2026+0.00%
Report Date
Feb 6, 2026
EPS Beat/Miss
-56.8%
Price Before
$26.00
Price After
$26.00
Q4 FY2025+0.00%
Report Date
Nov 10, 2025
EPS Beat/Miss
—
Price Before
$24.00
Price After
$24.00
Q3 FY2025+0.00%
Report Date
Aug 5, 2025
EPS Beat/Miss
—
Price Before
$28.09
Price After
$28.09
Q2 FY2025+6.77%
Report Date
May 12, 2025
EPS Beat/Miss
—
Price Before
$26.31
Price After
$28.09
Q1 FY2025+0.00%
Report Date
Feb 6, 2025
EPS Beat/Miss
—
Price Before
$26.31
Price After
$26.31
Q4 FY2024+0.00%
Report Date
Nov 8, 2024
EPS Beat/Miss
—
Price Before
$24.01
Price After
$24.01
Q3 FY2024+0.00%
Report Date
Aug 7, 2024
EPS Beat/Miss
—
Price Before
$27.92
Price After
$27.92
Avg Miss Reaction+0.00%
Beat Rate0 / 8 quarters
Largest Move+6.77% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: KKPCF ends December
Kaken Pharmaceutical Co., Ltd. (KKPCF) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $0.12 — missing the analyst consensus of $0.13 by -1.4%. The next KKPCF earnings date is expected around September 1, 2026.
Each quarter, investors track KKPCF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. KKPCF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
KKPCF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
KKPCF earnings · 5 questionsKaken Pharmaceutical Co., Ltd.'s next earnings report is expected around September 1, 2026. KKPCF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; KKPCF historically reports after market close (AMC).
KKPCF earnings datewhen is KKPCF earningsKKPCF next earnings datewhen does KKPCF report earningsKKPCF earnings calendar
▸ Source: FMP · Kaken Pharmaceutical Co., Ltd. SEC filings · US GAAP · Kaken Pharmaceutical Co., Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026